Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in tranplantation patients

ABSTRACT

The described invention comprises a method for detecting the onset or monitoring the recurrence of chronic graft versus host disease (cGVHD) in a transplantation patient. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from the transplantation patient and analyzing the isolated PBMCs to detect a biomarker specific for a donor cell. The detection of the biomarker is indicative of the onset or recurrence of cGVHD in the transplantation patient.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Divisional Application of U.S. patent applicationSer. No. 13/796,344 filed on Mar. 12, 2013, which claims the benefit ofpriority to U.S. Provisional Application No. 61/758,650 filed Jan. 30,2013, the contents of which are incorporated by reference in theirentirety.

STATEMENT OF GOVERNMENT FUNDING

This invention was made with government support under National HeartLung and Blood Institute R21 HL084318 and National Cancer Institute P01CA049605. The government has certain rights in the invention.

FIELD OF INVENTION

The described invention generally relates to a method for detecting theonset and monitoring the recurrence of chronic graft versus host diseasein transplantation patients.

BACKGROUND OF THE INVENTION

Allogeneic hematopoietic cell transplantation (allo-HCT) is apotentially curative therapy for patients with leukemia or lymphoma.However, chronic graft versus host-disease (cGVHD) remains a significantcause of late morbidity and mortality (Socie G (2011) Chronic GVHD: anew risk score? Blood 117:6408-6409; Socie G, et al. (2011) Chronicgraft-versus-host disease: long-term results from a randomized trial ongraftversus-host disease prophylaxis with or without anti-T-cellglobulin ATG-Fresenius. Blood 117:6375-6382; Kohrt H E, et al. (2009)TLI and ATG conditioning with low risk of graft-versus-host diseaseretains antitumor reactions after allogeneic hematopoietic celltransplantation from related and unrelated donors. Blood 114:1099-1109;Arai S, et al. (2012) Prophylactic rituximab after allogeneictransplantation decreases B-cell alloimmunity with low chronic GVHDincidence. Blood 119:6145-6154).

Several studies indicate that donor-derived alloreactive B and T cellsare involved in pathogenesis of cGVHD. In support of a B cell role (AraiS, et al. (2012) Prophylactic rituximab after allogeneic transplantationdecreases B-cell alloimmunity with low chronic GVHD incidence. Blood119:6145-6154; Allen J L, et al. (2012) B cells from patients withchronic GVHD are activated and primed for survival via BAFF-mediatedpathways. Blood 120:2529-2536; Kuzmina Z, et al. (2011) Significantdifferences in B-cell subpopulations characterize patients with chronicgraft-versus-host disease-associated dysgammaglobulinemia. Blood117:2265-2274; Sarantopoulos S, et al. (2007) High levels of B-cellactivating factor in patients with active chronic graftversus-hostdisease. Clin Cancer Res 13:6107-6114; Sarantopoulos S, et al. (2011)Recovery of B-cell homeostasis after rituximab in chronicgraft-versus-host disease. Blood 117:2275-2283; She K, et al. (2007)Altered Toll-like receptor 9 responses in circulating B cells at theonset of extensive chronic graft-versus-host disease. Biol Blood MarrowTransplant 13:386-397), the presence of circulating autoantibody(Sarantopoulos S, et al. (2009) Altered B-cell homeostasis and excessBAFF in human chronic graft-versushost disease. Blood 113:3865-74) andalloantibody (Miklos D B, et al. Antibody response to DBY minorhistocompatibility antigen is induced after allogeneic stem celltransplantation and in healthy female donors. Blood 103:353-359;Wechalekar A, Cranfield T, Sinclair D, and Ganzckowski M (2005)Occurrence of autoantibodies in chronic graft vs. host disease afterallogeneic stem cell transplantation. Clin Lab Haematol 27:247-249) havebeen associated with development of cGVHD. Specifically, predominant Bcell subsets have been demonstrated in patients with cGVHD andidentified in different studies as naïve (Kuzmina Z, et al. (2011)Significant differences in B-cell subpopulations characterize patientswith chronic graft-versus-host disease-associated dysgammaglobulinemia.Blood 117:2265-2274) and post germinal center B cells (Sarantopoulos S,et al. (2007) High levels of B-cell activating factor in patients withactive chronic graftversus-host disease. Clin Cancer Res 13:6107-6114;Sarantopoulos S, et al. (2011) Recovery of B-cell homeostasis afterrituximab in chronic graft-versus-host disease. Blood 117:2275-2283;Sarantopoulos S, et al. (2009) Altered B-cell homeostasis and excessBAFF in human chronic graft-versushost disease. Blood 113:3865-74). Inaddition, B cell related markers and antibodies have been recognized asbiomarkers for characterization and scoring cGVHD (Schultz K R, et al.(2006) Toward biomarkers for chronic graft-versus-host disease: NationalInstitutes of Health consensus development project on criteria forclinical trials in chronic graft-versus-host disease: III. BiomarkerWorking Group Report. Biol Blood Marrow Transplant 12:126-137; Socie G(2011) Chronic GVHD: B cells come of age. Blood 117:2086-2087). Finally,Rituximab, which depletes B cells, has been successfully used as cGVHDtherapy (Sarantopoulos S, et al. (2011) Recovery of B-cell homeostasisafter rituximab in chronic graft-versus-host disease. Blood117:2275-2283; Deneberg S, Lerner R, Ljungman P, Ringden O, and HagglundH (2007) Relapse of preB-ALL after rituximab treatment for chronic graftversus host disease: implications for its use? Med Oncol 24:354-356;Kharfan-Dabaja, M A and Bazarbachi A (2010) Emerging role of CD20blockade in allogeneic hematopoietic cell transplantation. Biol BloodMarrow Transplant 16:1347-1354; Kharfan-Dabaja M A, et al. (2009)Efficacy of rituximab in the setting of steroid-refractory chronicgraftversus-host disease: a systematic review and meta-analysis. BiolBlood Marrow Transplant 15:1005-1013; Zaja, F, et al. (2007) Treatmentof refractory chronic GVHD with rituximab: a GITMO study. Bone MarrowTransplant 40:273-277; Cutler C, et al. (2006) Rituximab forsteroid-refractory chronic graft-versus-host disease. Blood 108:756262).

Previous studies by our group have shown alloantibody responses occur inmale HCT patients with female donors (F→M). These responses includedonor derived alloreactive IgG that recognizes one or more Y chromosomeencoded proteins (H-Y antigens), including the DDX3Y protein (referredto hereafter as DBY) and its immunodominant DBY-2 peptide, which we usein studies here. In addition, donor-derived anti-DBY antibodies appearin serum in association with cGVHD in F→M patients implicatingalloreactive B cells in cGVHD pathogenesis (Miklos D B, et al. Antibodyresponse to DBY minor histocompatibility antigen is induced afterallogeneic stem cell transplantation and in healthy female donors. Blood103:353-359; Miklos D B, et al. (2005) Antibody responses to H-Y minorhistocompatibility antigens correlate with chronic graft-versus-hostdisease and disease remission. Blood 105:2973-2978). In order to testthe hypothesis that H-Y specific B cells contribute to cGVHDpathogenesis, we have developed an H-Y specific FACS stain for theirisolation and characterization.

Here, we demonstrate that 6 months after F→M transplant, more than halfof 28 male patients with female donors develop circulating B cells whosesurface IgM and IgG receptors specifically bind DBY-2, and hence arepoised to undergo class switch and differentiate to plasma cells thatproduce IgG anti-DBY-2 antibodies. Further, we show that their presencein circulation is strongly associated with the development of cGVHD(p=0.004), that is, the overwhelming majority (15/16) of patients whohave DBY-2 specific B cells either have or will develop cGVHD within 1-3months. In contrast, only about half (5/12) of patients who do not havethese B cells develop cGVHD. We detected immunoglobulin (Ig) M and IgGanti-DBY-2 B cells in all but 2 of the patients who later developedcirculating IgG anti-DBY-2 (p=0.002).

As is usual in studies with antigen binding B cells in the mouse (YangY, et al. (2012) Antigen-specific memory in B-1a and its relationship tonatural immunity. Proc Natl Acad Sci USA 109:5388-5393; Yang Y, et al.(2012) Antigen-specific antibody responses in B-1a and theirrelationship to natural immunity. Proc Natl Acad Sci USA 109:5382-5387),the amount of the antigen bound to the B cells is strongly correlatedwith the amount of surface Ig on the cells, which at the time point weexamined is exclusively IgM and IgD associated mainly with Igλ lightchains. However, even though these cells have most likely arisen inresponse to antigenic stimulation (DBY-2 on the male patient's cellsstimulating female donor B cells), they express a phenotype(CD19+IgM+IgD+CD38+ and CD27-) commonly taken as characteristic oftransitional B cells that have recently entered circulation from bonemarrow.

The prospective monitoring of anti-DBY-2 B cells may direct a moreeffective schedule for alloreactive B cell depletion therapy towards agoal of cGVHD prevention. Likewise, DBY-2 B cell monitoring may helpelucidate whether current in vivo B cell depletion therapy for cGVHDeffectively depletes these alloreactive B cells or if they persist andproliferate when cGVHD recurs.

SUMMARY OF THE INVENTION

B cells are known to play an important role in pathogenesis of humanchronic graft-versus-host disease (cGVHD). Our group has previouslyshown that IgG allo-antibodies recognize Y chromosome encoded proteins(H-Y) and a dominant H-Y epitope (DBY-2) detectable 6-12 months aftertransplant in male patients who receive grafts from female donors (F→MHCT). Here we present fluorescence-activated cell sorting (FACS) studiesof peripheral blood mononuclear cells (PBMC) collected 6 monthspost-transplant showing that 16/28 (57%) F→M HCT patients havecirculating donor B cells that express B cell receptor (mainly IgM andIgλ) specific for DBY-2. The detection of these DBY-2 B cells 6 monthsafter HCT are associated with chronic graft versus host disease (cGVHD)development (p=0.004). Specifically, 15 of 16 F→M with DBY-2 B cellsdeveloped cGVHD. In contrast, cGVHD developed in only 5 of the 12 whodid not have DBY-2 B cells detected. This is the first demonstration ofcirculating human B cells binding an alloantigen (DBY-2) and the firstdemonstration that these DBY-2 specific B cells appear prior todevelopment of cGVHD in roughly half of the F→M patients. Our studysuggests that detection of anti DBY-2 B cells may predict cGVHD.

The present disclosure provides methods, compositions and kits useful toprovide evidence of onset and to monitor recurrence of chronic graftversus host disease (cGVHD) in subjects who have received ahematopoietic cell transplantation allograft.

According to one aspect, the described invention provides a method forwarning of onset of chronic graft versus host disease (cGvHD) prior toappearance of symptoms of cGvHD in a patient following a hematopoieticcell transplantation therapy with a hematopoietic cell allograft,comprising isolating peripheral blood mononuclear cells (PBMCs) from thepatient at a time after the therapy; analyzing the isolated PBMCs, andspecifically detecting a first biomarker expressed by circulating cellsof the patient that reacts with a second biomarker expressed bygenetically distinct cells, wherein the detecting of the cells thatexpress the first biomarker indicates likely imminent onset of cGVHD inthe patient; and initiating immune therapy to mitigate symptoms of cGvHDresulting from the transplant.

According to another aspect, the described invention provides a methodfor warning of recurrence of chronic graft versus host disease (cGvHD)prior to appearance of symptoms of cGvHD in a patient who, followinghematopoietic cell transplantation therapy with a hematopoietic cellallograft, developed and was treated for cGvHD, which is in remission,comprising isolating peripheral blood mononuclear cells (PBMCs) from thepatient at a time after the therapy; analyzing the isolated PBMCs, andspecifically detecting a first biomarker expressed by circulating cellsof the patient that reacts with a second biomarker expressed bygenetically distinct cells, wherein the detecting of the cells thatexpress the first biomarker indicates likely imminent onset of cGvHD inthe patient; and initiating immune therapy to treat the recurrence ofthe cGvHD resulting from the transplant.

According to one embodiment, the circulating cells expressing the firstbiomarker are B lymphocytes with receptors that detect the firstbiomarker. According to another embodiment, the circulating cells arederived from the hematopoietic cell allograft.

According to one embodiment, the first biomarker is an antibody, thehematopoietic cell allograft contains cells that express the antibody,and the antibody reacts with the second biomarker expressed by thepatient's cells.

According to one embodiment, the second biomarker is a Y-chromosomeencoded H-Y antigen. According to another embodiment, the H-Y antigen isDBY-2.

According to one embodiment, the recipient patient is male, therecipient's cells express the second biomarker, and the second biomarkeris the Y-chromosome encoded H-Y antigen, the donor is female, thedonor's cells express the first biomarker, and the first biomarker is anantibody, which binds to the second biomarker, which is the H-Y antigenexpressed by the patient's cells, wherein the recipient patient anddonor are genetically distinct. According to another embodiment, thedonor's cells that express the first biomarker are B lymphocytes.According to another embodiment, the phenotype of the B lymphocytes isCD19⁺.

According to one embodiment, the time after therapy for detecting thefirst biomarker expressed by circulating cells of the patient is within1 year after transplantation. According to another embodiment, the timeafter therapy for detecting the first biomarker expressed by circulatingcells of the patient is within 180 days after transplantation. Accordingto another embodiment, the time after therapy for detecting the firstbiomarker expressed by circulating cells of the patient is within 155days after transplantation. According to another embodiment, the timeafter therapy for detecting the first biomarker expressed by circulatingcells of the patient is within 90 days after transplantation.

According to one embodiment, the detecting of the first biomarkerexpressed by circulating cells of the patient precedes development ofcirculating antibodies to a donor cell antigen in the patient.

According to one embodiment, the analyzing step is performed using flowcytometry.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts gated FACS data for a representative 6 month samplecontaining 0.8% DBY-2 binding B cells that are shown staining positivefor CD19 and DBY-2. The Fluorescence Minus One (FMO) control gateexcludes cells that non-specifically bound the fluoro-chrome coupledDBY-2 peptide (Y-axis) and define the DBY-2 binding threshold. DBY-2binding B cells are shown to express Igκ or Igλ light chains 180 daysfollowing F→M HCT.

FIG. 2A-FIG. 2B depicts anti-DBY-2 B cell development, anti-DBY-2 Ig,and severity of cGVHD in 28 F→M HCT patients. FIG. 2A schematicallyillustrates the temporal development of anti-DBY-2 B cells and cGVHD for28 F→M patients with clinical follow-up through 730 days (X-axis).Filled circles indicate the presence of DBY-2 specific B cells; circlesize reflects the percentage of these B cells among PBMC lymphocytes.Open circles indicate that anti-DBY-2 B cell frequencies were belowdetectability (<0.1%) of PBMC lymphocytes. Solid lines indicate cGVHDonset and duration. “R” marks time of hematologic malignancy relapse.FIG. 2B schematically illustrates the frequency of DBY-2 B cellsdetected at 180 and 365 days are related to Ig development against DBY-2peptide epitope, full-length DBY protein, and cGVHD development. cGVHDpatients were ranked by frequency of DBY-2 B cells detected 180 daysfollowing transplant and secondarily by presence of IgG anti-DBY-2 inserum. Other columns include the unique Stanford Patient Number (SPN),each patient's NIH cGVHD score, the maximum IgM and IgG anti-DBY oranti-DBY-2 levels measured by ELISA within 1 year post HCT. The Figurelegends indicate the relative intensity of each value.

FIG. 3 depicts gated FACS data illustrating DBY-2 binding B cells aredetected in some F→M patients after HCT but not in healthy males andfemale donors. Data for a representative F→M HCT patient collected 180days post HCT (upper panel) and for health controls (lower 3 panels).Less than 0.1% DBY-2 specific B cells were detected in 15 normal maleand 8 female samples. The third row shows no DBY-2 specific B cells weredetected following pre-incubation of serum collected from F→M HCTcontaining high-titer anti-DBY-2 IgG with normal male donor PBMCs andsuggests DBY-2 staining observed after F→M HCT is not an indirect IgGmediated binding but rather cell specific IgM dependent binding.

FIG. 4 illustrates anti-DBY-2 B cell frequencies quantified 180 daysafter 28 F→M HCT. Y-axis in both the upper and lower panels shows therelative frequency of DBY-2 binding B cells in relation to total PBMClymphocytes shown on the X-axis (above) or in relation to cGVHD severity(below). Upper panel: open circles indicate cGVHD patients; closedcircles show similar data for patients who did not develop cGVHD. In thelower panel anti-DBY-2 B cell staining associates with any cGVHDdevelopment in comparison to none (p=0.004; Fisher exact test).

FIG. 5 illustrates that DBY-2 binding B cells secret IgG in presence ofT cells and DBY-antigen. FACS sorted DBY-2 binding B cells are incubatedin the absence (upper left panels) or in the presence (Upper rightpanels) of autologous T cells, IL-2, DBY-protein and BAFF. Relative IgGantibody levels for DBY-2 and DBY proteins are shown after 7 days ofincubation. Secreted IgG levels were determined in presence of thereagents as depicted below X-axis for n=9 first column, n=4 for secondcolumn, n=2 for third and subsequent conditions.

FIG. 6 depicts gated FACS data illustrating a phenotype of the DBY-2binding B cells. Singlet, live, lymphocyte, B cells are gated for thepresence of DBY-2 binding and Igλ. These cells are further shown to beIgD⁺, CD38⁺ and CD27⁻.

DETAILED DESCRIPTION OF THE INVENTION

The described invention can be better understood from the followingdescription of exemplary embodiments, taken in conjunction with theaccompanying figures and drawings. It should be apparent to thoseskilled in the art that the described embodiments of the presentinvention provided herein are merely exemplary and illustrative and notlimiting.

Definitions

Various terms used throughout this specification shall have thedefinitions set out herein.

The term “activation marker” as used herein, refers to an intracellularor cell surface marker that is highly associated with a particular celland is selectively upregulated during a physiological condition. Thephysiological condition may be exposure to a substance, an allergen, adrug, a protein or a chemical, or other stimuli, or removal of astimuli, a substance, a protein, an allergen, a drug or a chemical.

The term “antigen” and its various grammatical forms refers to anysubstance that can stimulate the production of antibodies and/or cancombine specifically with them. The term “antigenic determinant” or“epitope” as used herein refers to an antigenic site on a molecule.

The term “autologous” as used herein, means derived from the sameorganism.

The term “allogeneic” as used herein, refers to being geneticallydifferent although belonging to or obtained from the same species.

Antibodies:

Antibodies are serum proteins the molecules of which possess small areasof their surface that are complementary to small chemical groupings ontheir targets. These complementary regions (referred to as the antibodycombining sites or antigen binding sites) of which there are at leasttwo per antibody molecule, and in some types of antibody molecules ten,eight, or in some species as many as 12, may react with theircorresponding complementary region on the antigen (the antigenicdeterminant or epitope) to link several molecules of multivalent antigentogether to form a lattice.

The basic structural unit of a whole antibody molecule consists of fourpolypeptide chains, two identical light (L) chains (each containingabout 220 amino acids) and two identical heavy (H) chains (each usuallycontaining about 440 amino acids). The two heavy chains and two lightchains are held together by a combination of noncovalent and covalent(disulfide) bonds. The molecule is composed of two identical halves,each with an identical antigen-binding site composed of the N-terminalregion of a light chain and the N-terminal region of a heavy chain. Bothlight and heavy chains usually cooperate to form the antigen bindingsurface.

Human antibodies show two kinds of light chains, κ and λ; individualmolecules of immunoglobulin generally are only one or the other. Innormal serum, 60% of the molecules have been found to have κdeterminants and 30 percent λ. Many other species have been found toshow two kinds of light chains, but their proportions vary. For example,in the mouse and rat, λ chains comprise but a few percent of the total;in the dog and cat, κ chains are very low; the horse does not appear tohave any κ chain; rabbits may have 5 to 40% λ, depending on strain andb-locus allotype; and chicken light chains are more homologous to λ thanκ.

In mammals, there are five classes of antibodies, IgA, IgD, IgE, IgG,and IgM, each with its own class of heavy chain—α (for IgA), δ (forIgD), ε (for IgE), γ (for IgG) and μ (for IgM). In addition, there arefour subclasses of IgG immunoglobulins (IgG1, IgG2, IgG3, IgG4) havingγ1, γ2, γ3, and γ4 heavy chains respectively. In its secreted form, IgMis a pentamer composed of five four-chain units, giving it a total of 10antigen binding sites. Each pentamer contains one copy of a J chain,which is covalently inserted between two adjacent tail regions.

All five immunoglobulin classes differ from other serum proteins in thatthey show a broad range of electrophoretic mobility and are nothomogeneous. This heterogeneity—that individual IgG molecules, forexample, differ from one another in net charge—is an intrinsic propertyof the immunoglobulins.

An antigenic determinant or epitope is an antigenic site on a molecule.Sequential antigenic determinants/epitopes essentially are linearchains. In ordered structures, such as helical polymers or proteins, theantigenic determinants/epitopes essentially would be limited regions orpatches in or on the surface of the structure involving amino acid sidechains from different portions of the molecule which could come close toone another. These are conformational determinants.

The principle of complementarity, which often is compared to the fittingof a key in a lock, involves relatively weak binding forces (hydrophobicand hydrogen bonds, van der Waals forces, and ionic interactions), whichare able to act effectively only when the two reacting molecules canapproach very closely to each other and indeed so closely that theprojecting constituent atoms or groups of atoms of one molecule can fitinto complementary depressions or recesses in the other.Antigen-antibody interactions show a high degree of specificity, whichis manifest at many levels. Brought down to the molecular level,specificity means that the combining sites of antibodies to an antigenhave a complementarity not at all similar to the antigenic determinantsof an unrelated antigen. Whenever antigenic determinants of twodifferent antigens have some structural similarity, some degree offitting of one determinant into the combining site of some antibodies tothe other may occur, and that this phenomenon gives rise tocross-reactions. Cross reactions are of major importance inunderstanding the complementarity or specificity of antigen-antibodyreactions. Immunological specificity or complementarity makes possiblethe detection of small amounts of impurities/contaminations amongantigens. The term “cross-reactivity” as used herein refers tosituations in which antigenic determinants of two different antigenshave some structural similarity, as a result of which some degree offitting of one determinant into the combining site of some antibodies tothe other may occur.

Monoclonal antibodies (mAbs) can be generated by fusing mouse spleencells from an immunized donor with a mouse myeloma cell line to yieldestablished mouse hybridoma clones that grow in selective media. Ahybridoma cell is an immortalized hybrid cell resulting from the invitro fusion of an antibody-secreting B cell with a myeloma cell. Invitro immunization, which refers to primary activation ofantigen-specific B cells in culture, is another well-established meansof producing mouse monoclonal antibodies.

Diverse libraries of immunoglobulin heavy (VH) and light (Vκ and Vλ)chain variable genes from peripheral blood lymphocytes also can beamplified by polymerase chain reaction (PCR) amplification. Genesencoding single polypeptide chains in which the heavy and light chainvariable domains are linked by a polypeptide spacer (single chain Fv orscFv) can be made by randomly combining heavy and light chain V-genesusing PCR. A combinatorial library then can be cloned for display on thesurface of filamentous bacteriophage by fusion to a minor coat proteinat the tip of the phage.

The technique of guided selection is based on human immunoglobulin Vgene shuffling with rodent immunoglobulin V genes. The method entails(i) shuffling a repertoire of human λ light chains with the heavy chainvariable region (VH) domain of a mouse monoclonal antibody reactive withan antigen of interest; (ii) selecting half-human Fabs on that antigen(iii) using the selected λ light chain genes as “docking domains” for alibrary of human heavy chains in a second shuffle to isolate clone Fabfragments having human light chain genes; (v) transfecting mouse myelomacells by electroporation with mammalian cell expression vectorscontaining the genes; and (vi) expressing the V genes of the Fabreactive with the antigen as a complete IgG1, λ antibody molecule in themouse myeloma.

The term “biomarkers” (or “biosignatures”) as used herein, refers topeptides, proteins, nucleic acids, antibodies, genes, metabolites, orany other substances used as indicators of a biologic state. It is acharacteristic that is measured objectively and evaluated as a cellularor molecular indicator of normal biologic processes, pathogenicprocesses, or pharmacologic responses to a therapeutic intervention.

The term “pre B lymphocyte” refers to an early B lymphoid type cell thatis recognized by immunofluorescence as a μ positive, L chain negativebone marrow cell.

The term “B lymphocyte” or “B cell” refers to a short livedimmunologically important lymphocyte that is not thymus dependent and isinvolved in humoral immunity. It expresses immunoglobulins on itssurface but does not release them. A mature B lymphocyte can beactivated by the binding of an antigen to cell surface receptors, whichinduces proliferation of the cell, resulting in a clone of cellsspecific for that antigen. With interaction with helper T lymphocytes,these cells then can differentiate to mature plasma cells, which secreteimmunoglobulin molecules.

The term “cytokine” as used herein, refers to small soluble proteinsubstances secreted by cells which have a variety of effects on othercells. Cytokines mediate many important physiological functionsincluding growth, development, wound healing, and the immune response.They act by binding to their cell-specific receptors located in the cellmembrane, which allows a distinct signal transduction cascade to startin the cell, which eventually will lead to biochemical and phenotypicchanges in target cells. Generally, cytokines act locally. They includetype I cytokines, which encompass many of the interleukins, as well asseveral hematopoietic growth factors; type II cytokines, including theinterferons and interleukin-10; tumor necrosis factor (“TNF”)-relatedmolecules, including TNFα and lymphotoxin; immunoglobulin super-familymembers, including interleukin 1 (“IL-1”); and the chemokines, a familyof molecules that play a critical role in a wide variety of immune andinflammatory functions. The same cytokine can have different effects ona cell depending on the state of the cell. Cytokines often regulate theexpression of, and trigger cascades of, other cytokines.

The term “cell surface marker” as used herein, refers to an antigenicdeterminant or epitope found on the surface of a specific type of cell.Cell surface markers can facilitate the characterization of a cell type,its identification, and its isolation. Cell sorting techniques are basedon cellular biomarkers where a cell surface marker(s) may be used foreither positive selection or negative selection, i.e., for inclusion orexclusion, from a cell population.

Cluster of Differentiation

The cluster of differentiation (CD) system is a protocol used for theidentification of cell surface molecules present on white blood cells.CD molecules can act in numerous ways, often acting as receptors orligands; by which a signal cascade is initiated, altering the behaviorof the cell. Some CD proteins do not play a role in cell signaling, buthave other functions, such as cell adhesion. Generally, a proposedsurface molecule is assigned a CD number once two specific monoclonalantibodies (mAb) are shown to bind to the molecule. If the molecule hasnot been well-characterized, or has only one mAb, the molecule usuallyis given the provisional indicator “w.”

The CD system nomenclature commonly used to identify cell markers thusallows cells to be defined based on what molecules are present on theirsurface. These markers often are used to associate cells with certainimmune functions. While using one CD molecule to define populations isuncommon, combining markers has allowed for cell types with veryspecific definitions within the immune system. There are more than 350CD molecules identified for humans.

CD molecules are utilized in cell sorting using various methods,including flow cytometry. Cell populations usually are defined using a“+” or a “−” symbol to indicate whether a certain cell fractionexpresses (“+”) or lacks (“−”) a CD molecule. For example, a “CD34+,CD31−” cell is one that expresses CD34, but not CD31. Table 1 showscommonly used markers employed by skilled artisans to identify andcharacterize differentiated white blood cell types:

Type of Cell CD Markers Stem cells CD34+, CD31− All leukocyte groupsCD45+ Granulocyte CD45+, CD15+ Monocyte CD45+, CD14+ T lymphocyte CD45+,CD3+ T helper cell CD45+, CD3+, CD4+ Cytotoxic T cell CD45+, CD3+, CD8+B lymphocyte CD45+, CD19+ or CD45+, CD20+ Thrombocyte CD45+, CD61+Natural killer cell CD16+, CD56+, CD3−

CD molecules used in defining leukocytes are not exclusively markers onthe cell surface. Most CD molecules have an important function, althoughonly a small portion of known CD molecules have been characterized. Forexample, there are over 350 CD for humans identified thus far.

CD3 (TCR complex) is a protein complex composed of four distinct chains.In mammals, the complex contains a CD3γ chain, a CD3δ chain, and twoCD3ε chains, which associate with the T cell receptor (TCR) and theζ-chain to generate an activation signal in T lymphocytes. Together, theTCR, the ζ-chain and CD3 molecules comprise the TCR complex. Theintracellular tails of CD3 molecules contain a conserved motiff known asthe immunoreceptor tyrosine-based activation motif (ITAM), which isessential for the signaling capacity of the TCR. Upon phosphorylation ofthe ITAM, the CD3 chain can bind ZAP70 (zeta associated protein), akinase involved in the signaling cascade of the T cell.

CD14 is a cell surface protein expressed mainly by macrophages and, to alesser extent, neutrophil granulocytes. CD14+ cells are monocytes thatcan differentiate into a host of different cells; for example,differentiation to dendritic cells is promoted by cytokines such asGM-CSF and IL-4. CD14 acts as a co-receptor (along with toll-likereceptor (TLR) 4 and lymphocyte antigen 96 (MD-2)) for the detection ofbacterial lipopolysaccharide (LPS). CD14 only can bind LPS in thepresence of lipopolysaccharide binding protein (LBP).

CD15 (3-fucosyl-N-acetyl-lactosamine; stage specific embryonic antigen 1(SSEA-1)) is a carbohydrate adhesion molecule that can be expressed onglycoproteins, glycolipids and proteoglycans. CD15 commonly is found onneutrophils and mediates phagocytosis and chemotaxis.

CD16 is an Fc receptor (FcγRIIIa and FcγRIIIb) found on the surface ofnatural killer cells, neutrophil polymorphonuclear leukocytes, monocytesand macrophages. Fc receptors bind to the Fc portion of IgG antibodies.

CD19 is a human protein expressed on follicular dendritic cells and Bcells. This cell surface molecule assembles with the antigen receptor ofB lymphocytes in order to decrease the threshold for antigenreceptor-dependent stimulation. It generally is believed that, uponactivation, the cytoplasmic tail of CD19 becomes phosphorylated, whichallows binding by Src-family kinases and recruitment of phosphoinositide3 (PI-3) kinases (See,https://www.beckmancoulter.com/wsrportal/wsrportal.portal?_nfpb=true&_windowLabel=UCM_RENDERER&_urlType=render&wlpUCM_RENDERER_path=%2Fwsr%2Fresearch-and-discovery%2Fproducts-and-services%2Fflow-cytometry%2Fb-cells%2Findex.htm).

CD20 is a non-glycosylated phosphoprotein expressed on the surface ofall mature B-cells. Studies suggest that CD20 plays a role in thedevelopment and differentiation of B-cells into plasma cells. CD20 isencoded by a member of the membrane-spanning 4A gene family (MS4A).Members of this protein family are characterized by common structuralfeatures and display unique expression patterns among hematopoieticcells and nonlymphoid tissues.

CD27 normally is found on most peripheral blood T lymphocytes, medullarythymocytes and a subpopulation of circulating B lymphocytes. CD27 is amember of the TNF-receptor superfamily. This receptor is required forthe generation and maintenance of T cell immunity. CD27 binds CD70 andplays a key role in regulating B cell activation and immunoglobulinsynthesis. CD27 transduces signals that lead to the activation ofNF-kappaB and MAPK8/JNK (See, http://www.ncbi.nlm.nih.gov/gene/939 andhttp://www.bdbiosciences.com/ptProduct.jsp?prodId=22387).

CD31 (platelet/endothelial cell adhesion molecule; PECAM1) normally isfound on endothelial cells, platelets, macrophages and Kupffer cells,granulocytes, T cells, natural killer cells, lymphocytes,megakaryocytes, osteoclasts and neutrophils. CD31 has a key role intissue regeneration and in safely removing neutrophils from the body.Upon contact, the CD31 molecules of macrophages and neutrophils are usedto communicate the health status of the neutrophil to the macrophage.

CD34 is a monomeric cell surface glycoprotein normally found onhematopoietic cells, endothelial progenitor cells, endothelial cells ofblood vessels, and mast cells. The CD34 protein is a member of a familyof single-pass transmembrane sialomucin proteins and functions as acell-cell adhesion factor. Studies suggest that CD34 also may mediatethe attachment of stem cells to bone marrow extracellular matrix ordirectly to stromal cells.

CD38 is a multifunctional ectoenzyme expressed on hematopoietic cells, Bcells, T cells, Natural Killer cells, monocytes and macrophages. CD38functions in cell adhesion, signal transduction and calcium signaling(See, http://www.ncbi.nlm.nih.gov/gene/952).

CD45 (protein tyrosine phosphatase, receptor type, C; PTPRC) cellsurface molecule is expressed specifically in hematopoietic cells. CD45is a protein tyrosine phosphatase (PTP) with an extracellular domain, asingle transmembrane segment, and two tandem intracytoplasmic catalyticdomains, and thus belongs to receptor type PTP. Studies suggest it is anessential regulator of T-cell and B-cell antigen receptor signaling thatfunctions by direct interaction with components of the antigen receptorcomplexes, or by activating various Src family kinases required forantigent receptor signaling. CD45 also suppresses JAK kinases, and thusfunctions as a regulator of cytokine receptor signaling. The CD45 familyconsists of multiple members that are all products of a single complexgene. Various known isoforms of CD45 include: CD45RA, CD45RB, CD45RC,CD45RAB, CD45RAC, CD45RBC, CD45RO, and CD45R (ABC). Different isoformsmay be found on different cells. For example, CD45RA is found on naïve Tcells and CD45RO is found on memory T cells (See,https://www.beckmancoulter.com/wsrportal/wsrportal.portal?_nfpb=true&_windowLabel=UCM_RENDERER&_urlType=render&wlpUCM_RENDERER_path=%2Fwsr%2Fresearch-and-discovery%2Fproducts-and-services%2Fflow-cytometry%2Fb-cells%2Findex.htm).

CD56 (neural cell adhesion molecule, NCAM) is a homophilic bindingglycoprotein expressed on the surface of neurons, glia, skeletal muscleand natural killer cells. It generally is believed that NCAM has a rolein cell-cell adhesion, neurite outgrowth, and synaptic plasticity. Thereare three known main isoforms of NCAM, each varying only in theircytoplasmic domains: NCAM-120kDA (glycosylphopharidylino sitol (GPI)anchored); NCAM-140 kDa (short cytoplasmic domain); and NCAM (longcytoplasmic domain). The different domains of NCAM have different roles,with the Ig domains being involved in homophilic binding to NCAM, andthe fibronection type III (FNIII) domains being involved in signalingleading to neurite outgrowth.

CD66b ((CGM1); CD67, CGM6, NCA-95) is a glycosylphosphatidylinositol(GPI)-linked protein that is a member of the immunoglobulin superfamilyand carcinoembryonic antigen (CEA)-like subfamily. CD66b, expressed ongranulocytes, generally is believed to be involved in regulatingadhesion and activation of human eosinophils.

CD61 (integrin (33; platelet glycoprotein IIIa; ITGB3) is a cell surfaceprotein composed of an α-chain and a β-chain. A given chain may combinewith multiple partners resulting in different integrins. CD61 is foundalong with the α IIb chain in platelets and is known to participate incell adhesion and cell-surface mediated signaling.

CD63 (LAMP-3; ME491; MLA1; OMA81H) is a cell surface glycoprotein of thetransmembrane 4 superfamily (tetraspanin family). Many of these cellsurface receptors have four hydrophobic domains and mediate signaltransduction events that play a role in the regulation of celldevelopment, activation, growth and motility. CD63 forms complexes withintegrins and may function as a blood platelet activation marker. Itgenerally is believed that the sensitivity and specificity of measuringthe upregulation of CD63 alone, or as part of a combination, is notspecific enough to serve as a diagnostic marker for the diagnosis of IgEmediated allergy.

CD123 is the 70 kD transmembrane a chain of the cytokine interleukin-3(IL-3) receptor. Alone, CD123 binds IL-3 with low affinity; when CD123associates with CDw131 (common β chain), it binds IL-3 with highaffinity. CD123 does not transduce intracellular signals upon bindingIL-3 and requires the β chain for this function. CD123 is expressed bymyeloid precursors, macrophages, dendritic cells, mast cells, basophils,megakaryocytes, and some B cells CD123 induces tyrosine phosphorylationwithin the cell and promotes proliferation and differentiation withinthe hematopoietic cell lines.

CD294 (G protein-coupled receptor 44; GPR44; CRTh2; DP2) is an integralmembrane protein. This chemoattractant receptor homologous molecule isexpressed on T helper type-2 cells. The transmembrane domains of theseproteins mediate signals to the interior of the cell by activation ofheterotrimeric G proteins that in turn activate various effectorproteins that ultimately result a physiologic response.

The term “cytometry” as used herein, refers to a process in whichphysical and/or chemical characteristics of single cells, or byextension, of other biological or nonbiological particles in roughly thesame size or stage, are measured. In flow cytometry, the measurementsare made as the cells or particles pass through the measuring apparatus(a flow cytometer) in a fluid stream. A cell sorter, or flow sorter, isa flow cytometer that uses electrical and/or mechanical means to divertand to collect cells (or other small particles) with measuredcharacteristics that fall within a user-selected range of values.

The term “differential label” as used herein, generally refers to astain, dye, marker, antibody or antibody-dye combination, orintrinsically fluorescent cell-associated molecule, used to characterizeor contrast components, small molecules, macromolecules, e.g., proteins,and other structures of a single cell or organism. The term “dye” (alsoreferred to as “fluorochrome” or “fluorophore”) as used herein refers toa component of a molecule which causes the molecule to be fluorescent.The component is a functional group in the molecule that absorbs energyof a specific wavelength and re-emits energy at a different (but equallyspecific) wavelength. The amount and wavelength of the emitted energydepend on both the dye and the chemical environment of the dye. Manydyes are known, including, but not limited to, FITC, R-phycoerythrin(PE), PE-Texas Red Tandem, PE-Cy5 Tandem, propidium iodem, EGFP, EYGP,ECF, DsRed, allophycocyanin (APC), PerCp, SYTOX Green, courmarin, AlexaFluors (350, 430, 488, 532, 546, 555, 568, 594, 633, 647, 660, 680, 700,750), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, Hoechst 33342, DAPI, Hoechst33258, SYTOX Blue, chromomycin A3, mithramycin, YOYO-1, SYTOX Orange,ethidium bromide, 7-AAD, acridine orange, TOTO-1, TO-PRO-1, thiazoleorange, TOTO-3, TO-PRO-3, thiazole orange, propidium iodide (PI), LDS751, Indo-1, Fluo-3, DCFH, DHR, SNARF, Y66F, Y66H, EBFP, GFPuv, ECFP,GFP, AmCyanl, Y77W, S65A, S65C, S65L, S65T, ZsGreenl, ZsYellowl, DsRed2,DsRed monomer, AsRed2, mRFP1, HcRedl, monochlorobimane, calcein, theDyLight Fluors, cyanine, hydroxycoumarin, aminocoumarin,methoxycoumarin, Cascade Blue, Lucifer Yellow, NBD, PE-Cy5 conjugates,PE-Cy7 conjugates, APC-Cy7 conjugates, Red 613, fluorescein, FluorX,BODIDY-FL, TRITC, X-rhodamine, Lissamine Rhodamine B, Texas Red, TruRed,and derivatives thereof.

Flow Cytometry

Flow cytometry is a technique for counting, examining, and sortingmicroscopic particles suspended in a stream of fluid. It allowssimultaneous multi-parametric analysis of the physical and/or chemicalcharacteristics of single cells flowing through an optical and/orelectronic detection apparatus.

Flow cytometry utilizes a beam of light (usually laser light) of asingle wavelength that is directed onto a hydro-dynamically focusedstream of fluid. A number of detectors are aimed at the point where thestream passes through the light beam; one in line with the light beam(Forward Scatter or FSC) and several perpendicular to it (Side Scatter(SSC) and one or more fluorescent detectors). Each suspended particlepassing through the beam scatters the light in some way, and fluorescentchemicals found in the particle or attached to the particle may beexcited into emitting light at a lower frequency than the light source.This combination of scattered and fluorescent light is picked up by thedetectors, and by analyzing fluctuations in brightness at each detector(usually one for each fluorescent emission peak) it then is possible toderive various types of information about the physical and chemicalstructure of each individual particle. FSC correlates with the cellvolume and SSC depends on the inner complexity of the particle (i.e.shape of the nucleus, the amount and type of cytoplasmic granules or themembrane roughness).

FACS

The term “fluorescence-activated cell sorting” (also referred to as“FACS”), as used herein, refers to a method for sorting a heterogeneousmixture of biological cells into one or more containers, one cell at atime, based upon the specific light scattering and fluorescentcharacteristics of each cell.

Fluorescence-activated cell sorting (FACS) is a specialized type of flowcytometry. It provides a method for sorting a heterogeneous mixture ofbiological cells into two or more containers, one cell at a time, basedupon the specific light scattering and fluorescent characteristics ofeach cell. It provides fast, objective and quantitative recording offluorescent signals from individual cells as well as physical separationof cells of particular interest.

Utilizing FACS, a cell suspension is entrained in the center of anarrow, rapidly flowing stream of liquid. The flow is arranged so thatthere is a large separation between cells relative to their diameter. Avibrating mechanism causes the stream of cells to break into individualdroplets. The system is adjusted so that there is a low probability ofmore than one cell being in a droplet. Before the stream breaks intodroplets the flow passes through a fluorescence measuring station wherethe fluorescent character of interest of each cell is measured. Anelectrical charging ring or plane is placed just at the point where thestream breaks into droplets. A charge is placed on the ring based on theprior light scatter and fluorescence intensity measurements, and theopposite charge is trapped on the droplet as it breaks from the stream.The charged droplets then fall through an electrostatic deflectionsystem that diverts droplets into containers based upon their charge. Insome systems the charge is applied directly to the stream while a nearbyplane or ring is held at ground potential and the droplet breaking offretains charge of the same sign as the stream. The stream is thenreturned to neutral after the droplet breaks off.

The term “graft” as used herein, refers to any tissue or organ fortransplantation. The term “allograft” as used herein, refers to a graftobtained from a donor of the same species as, but with a differentgenetic make-up from, the recipient, for example, a tissue or organtransplantation between two humans.

The term “graft versus host” as used herein, refers to a systemicautoimmune syndrome resulting from cells of engrafted HCT mounting animmune response against the host. In human recipients of bone marrow, achronic GvHD syndrome is a major clinical problem, leading to fibrosis,pathology and autoantibodies. The syndrome occurs even in recipients ofautologous marrow, although in a milder form. See, e.g., Kennedy,Autologous graft versus host disease. Med. Oncol. 12: 149-15 (1995).Symptoms of chronic GvHD include, but are not limited to, dry eyes orvision changes, dry mouth, white patches inside the mouth, sensitivityto spicy foods, fatigue, muscle weakness, chronic pain, skin rash withraised, discolored areas, skin tightening or thickening, shortness ofbreath, vaginal dryness and/or weight loss.

The term “hematopoietic stem cell” as used herein, refers to a cellisolated from the blood or from the bone marrow that can renew itself,differentiate to a variety of specialized cells, mobilize out of thebone marrow into the circulating blood, and undergo programmed celldeath (apoptosis). In some embodiments of the described invention,hematopoietic stem cells derived from human subjects express at leastone type of cell surface marker, including, but not limited to CD34,CD38, HLA-DR, c-kit, CD59, Sca-1, Thy-1, and/or CXCR-4, or a combinationthereof.

The term “histocompatibility” as used herein, refers to a state ofimmunologic similarity (or identity) that permits successfulhomograft/allograft transplantation.

The term “major histocompatibility complex” (MHC) as used herein, refersto a group of linked loci, collectively termed H-2 complex in the mouseand HLA complex in humans, that codes for cell-surfacehistocompatibility antigens and is the principal determinant of tissuetype and transplant compatibility.

The term “minor histocompatibility complex” as used herein, refers togenes outside of MHC that are present on various chromosomes that encodeantigens contributing to graft rejection.

The term “H-Y antigen” as used herein, refers to an antigenic factor,dependent on the Y chromosome, responsible for the differentiation ofthe human embryo into the male phenotype by inducing the initiallybipotential embryonic gonad to develop into a testis; in the absence ofthis antigen, the indifferent gonad develops into an ovary. There are atleast two loci involved, an autosomal gene that generates the antigen(MIM*543170) and one that makes the receptor (MIM*143150).

The term “human leukocyte antigen (HLA)-DR” as used herein, refers to amajor histocompatibility complex (MHC) class II cell surface receptor.HLA-DR commonly is found on antigen-presenting cells such asmacrophages, B-cells, and dendritic cells. This cell surface molecule isa αβ heterodimer with each subunit containing 2 extracellular domains: amembrane spanning domain and a cytoplasmic tail. Both the α and β chainsare anchored in the membrane. The complex of HLA-DR and its ligand (apeptide of at least 9 amino acids) constitutes a ligand for the TCR.

The term “integrins” as used herein, refers to receptors that mediateattachment between a cell and the tissues surrounding it and areinvolved in cell-cell and cell-matrix interactions. In mammals, 18 α and8 β subunits have been characterized. Both α and β subunits contain twoseparate tails, both of which penetrate the plasma membrane and possesssmall cytoplasmic domains.

Integrin αM (ITGAM; CD11b); macrophage-1 antigen (Mac-1); complementreceptor 3 (CR3)) is a protein subunit of the heterodimeric integrinαMβ2 molecule. The second chain of αMβ2 is the common integrin β2subunit (CD18). αMβ2 is expressed on the surface of many leukocytesincluding monocytes, granulocytes, macrophages and natural killer cells.It generally is believed that αMβ2 mediates inflammation by regulatingleukocyte adhesion and migration. Further, αMβ2 is thought to have arole in phagocytosis, cell-mediated cytotoxicity, chemotaxis andcellular activation, as well as being involved in the complement systemdue to its capacity to bind inactivated complement component 3b (iC3b).The ITGAM subunit of integrin αMβ2 is involved directly in causing theadhesion and spreading of cells, but cannot mediate cellular migrationwithout the presence of the β2 (CD18) subunit.

The term “labeling” as used herein, refers to a process ofdistinguishing a compound, structure, protein, peptide, antibody, cellor cell component by introducing a traceable constituent. Commontraceable constituents include, but are not limited to, a fluorescentantibody, a fluorophore, a dye or a fluorescent dye, a stain or afluorescent stain, a marker, a fluorescent marker, a chemical stain, adifferential stain, a differential label, and a radioisotope.

The term “lymphocyte” refers to a white blood cell formed in lymphatictissue throughout the body and in normal adults making up about 22-28%of the total number of leukocytes in the circulating blood. Lymphocytesare divided into two principal groups, termed B lymphocytes and Tlymphocytes, based on their surface molecules and function.

Lymphocyte activation refers to stimulation of lymphocytes by specificantigens, nonspecific mitogens, or allogeneic cells resulting insynthesis of RNA, protein and DNA and production of lymphokines; it isfollowed by proliferation and differentiation of various effector andmemory cells. The soluble product of an activated B lymphocyte isimmmunoglobulins (antibodies). The soluble product of an activated Tlymphocyte is lymphokines.

The term “mitigate” as used herein, refers to a process of making lesssevere, serious, or painful.

The terms “peripheral blood mononuclear cells” or “PBMCs” are usedinterchangeably herein to refer to blood cells having a single roundnucleus such as, for example, a lymphocyte or a monocyte. PBMCs are acritical component in the immune system's responses to infections.

The term “stain” as used herein refers to a composition of a dye(s) orpigment(s) used to make a structure, a material, a cell, a cellcomponent, a membrane, a granule, a nucleus, a cell surface receptor, apeptide, a microorganism, a nucleic acid, a protein or a tissuedifferentiable.

The phrase “subject in need thereof” as used herein refers to a patientthat (i) will be administered at least one allograft, (ii) is receivingat least one allograft; or (iii) has received at least one allograft,and is at risk for GvHD, unless the context and usage of the phraseindicates otherwise.

The term “symptom” as used herein refers to a sign or an indication ofdisorder or disease, especially when experienced by an individual as achange from normal function, sensation, or appearance.

The T Cell Compartment Comprises Distinct T Cell Subsets:

The term “T lymphocyte” or “T cell” generally refers to a thymocytederived lymphocyte of immunologic importance that is long lived and isresponsible for cell mediated immunity. Cellular immunity, the domain ofT lymphocytes, is responsible for many immune reactions and is a majorelement in many autoimmune reactions. T cells are known to directly killtarget cells, to provide “help” for such killers, to activate otherimmune system cells (e.g., macrophages), to help B cells make anantibody response, to downmodulate the activities of various immunesystem cells, and to secrete cytokines, chemokines, and other mediators.

The type 1 and type 2 helper classes are defined by their cytokinesecretion profiles. T-helper 1 (Th1) cells, which are implicated in thestimulation of inflammation, produce IFN-gamma, GM-CSF, TNF-beta, andTNFα. TNF and IFN-gamma signals synergize in inducing an activated statein the macrophage, and lead to increased expression of adhesion andhoming molecules in the vascular endothelium, which recruit additionalblood-born leukocytes to the site of inflammation. (Paul, Fundamentalsof Immunol. p. 397). T helper 2 (Th-2) cells produce IL-4, IL-5, IL-10,and IL-13, and provide help for B cells in their activation anddifferentiation leading to the humoral immune response. (de WaalMalefyt, Immunity 31: 700-702 (2009)).

Regulatory T cells, either natural, induced, or Tr1 cells, produce IL-10and TGFβ, suppress the activation of effector T cells, and provide acounter-balance against uncontrolled and harmful T cell responses. Id.Th9 cells may provide additional help for mast cells through theproduction of IL-9. Id. Th17, an additional T cell subset, producesIL-17A, 17-17F, IL-22 and CCL20, which act on stromal and epithelialcells to induce a number of secondary effector molecules, such as G-CSF,which stimulates the production and mobilization of neutrophils, acutephase proteins, chemokines, and antimicrobial peptides. Id.

Naive T cells can differentiate into any of the distinct T cell subsetswhen activated in the presence of appropriate signals and cytokines. Theinduction of a maturation process in dendritic cells is a crucial stepfor efficient priming of naive T cells. There is an extensivecross-regulation between subsets to ensure that the appropriate T cellsubset is activated. Id.

The term “transplantation” as used herein, refers to implanting in onepart cells, a tissue or organ taken from another part or anotherindividual.

The described invention provides methods useful in warning of onset orrecurrence of chronic graft versus host disease (cGvHD) in a patientfollowing a hematopoietic cell transplantation therapy with ahematopoietic cell allograft.

According to one aspect, the described invention provides a method forwarning of onset of chronic graft versus host disease (cGvHD) prior toappearance of symptoms of cGvHD in a patient following a hematopoieticcell transplantation therapy with a hematopoietic cell allograft,comprising: (a) isolating peripheral blood mononuclear cells (PBMCs)from the patient at a time after the hematopoietic cell transplantationtherapy; (b) analyzing the isolated PBMCs, and specifically detecting afirst biomarker expressed by circulating cells of the patient thatreacts with a second biomarker expressed by genetically distinct cells,wherein the detecting of the cells that express the first biomarkerindicates likely imminent onset of cGVHD in the patient; and (c)initiating immune therapy to mitigate symptoms of cGvHD resulting fromthe transplant.

According to another aspect, the described invention provides a methodfor warning of recurrence of chronic graft versus host disease (cGvHD)prior to appearance of symptoms of cGvHD in a patient who, following ahematopoietic cell transplantation therapy with a hematopoietic cellallograft, developed and was treated for cGvHD, which is in remission,comprising: (a) isolating peripheral blood mononuclear cells (PBMCs)from the patient at a time after the hematopoietic cell transplantationtherapy; (b) analyzing the isolated PBMCs, and specifically detecting afirst biomarker expressed by circulating cells of the patient thatreacts with a second biomarker expressed by genetically distinct cells,wherein the detecting of the cells that express the first biomarkerindicates likely imminent onset of cGvHD in the patient; and (c)initiating immune therapy to treat the recurrence of the cGvHD resultingfrom the transplant.

Methods for isolating PBMCs are well-known in the art. Those skilled inthe art appreciate that there are many established protocols forisolating PBMCs from peripheral blood. Peripheral blood may be drawnconveniently via venipuncture. Isolation of PBMCs may include, but arenot limited to, cell elutriation and density-gradient separationprotocols. Exemplary density-gradient separation protocols employ, forexample, Ficoll®. Briefly, blood samples may be collected in sodiumheparin tubes (BD Biosciences, San Jose, Calif., Catalog No. 367874 orequivalent). Blood may be transferred to 50 mL conical tubes containing15 mL of Ficoll®-Paque PLUS (GE Healthcare, Waukesha, Wis., Catalog No.17-1440-03) and centrifuged at 800 rcf (1,900-2,000 rpm) for 20 minuteswith centrifuge break off. After centrifugation, the buffy coat layer(containing PBMCs) may be removed and transferred to a new 50 mL conicaltube. Phosphate-buffered saline (PBS) without calcium and magnesium(Gibco, Life Technologies, Carlsbad, Calif., Catalog No. 10010-023 orequivalent) may be added to the buffy coat layer so that the totalvolume in the conical tube is equal to 50 mL. The buffy coat layer inPBS may be centrifuged at 250 rcf (1,200 rpm) for 10 minutes withcentrifuge break applied. After centrifugation, the PBS may be aspiratedand the PBMC pellet may be resuspended in 48 mL of PBS. PBMCsresuspended in PBS may be centrifuged at 250 rcf (1,200 rpm) for 10minutes with centrifuge break applied. PBS may be aspirated and PBMCpellet resuspended in 12.5% Human Serum Albumin (HSA) (GeminiBio-Products, West Sacramento, Calif., Catalog No. 800-120 orequivalent) in RPMI medium (Sigma-Aldrich, St. Louis, Mo., Catalog No.R7388 or equivalent).

It is understood that PBMCs may be analyzed after isolation orcryopreserved for subsequent analysis. Those skilled in the artappreciate that there are many established protocols forcryopreservation of PBMCs. For example, 2× freezing media (10% HSA,Gemini Bio-Products, West Sacramento, Calif., Catalog No. 800-120 orequivalent; 20% Dimethylsulfoxide (DMSO), Sigma-Aldrich, St. Louis, Mo.,Catalog No. D2650 or equivalent; RPMI medium, Sigma-Aldrich, St. Louis,Mo., Catalog No. R7388 or equivalent) chilled to 4° C. may be addeddropwise to isolated PBMCs at 1×10⁷ viable cells/mL in 12.5% Human SerumAlbumin (HSA) (Gemini Bio-Products, West Sacramento, Calif., Catalog No.800-120 or equivalent) in RPMI medium (Sigma-Aldrich, St. Louis, Mo.,Catalog No. R7388 or equivalent) until the freezing media contains afinal concentration of 5% HSA, 10% DMSO in RPMI medium. PBMCs infreezing media may be aliquoted into cryovials (Nunc, Thermo Scientific,Waltham, Mass., Catalog No. 12-565-297 or equivalent) (1 mL/cryovial)and placed on ice. Cryovials containing 1 mL of PBMCs in freezing mediamay be placed in a pre-cooled freezing container (Nalgene, ThermoScientific, Waltham, Mass., Catalog No. 15-350-50 or equivalent) filledwith 70% ethanol (Sigma-Aldrich, St. Louis, Mo., Catalog No. 02877 orequivalent). The freezing container may be placed at −80° C. for 24hours before cryovials may be transferred to liquid nitrogen.

The described invention provides a method for warning of onset orrecurrence of cGvHD by detecting a first biomarker expressed bycirculating cells of the patient that reacts with a second biomarkerexpressed by genetically distinct cells. Possible sources of biomarkersinclude tissue biopsy and body fluids. Body fluids include, but are notlimited to, whole blood, plasma, serum, lymphatic fluid and the like.Possible biomarkers include, but are not limited to, peptides, proteins,glycoproteins, polysaccharides, nucleic acids, antibodies, genes,metabolites, and the like. Exemplary protein biomarkers include, but arenot limited to, transforming growth factor beta 1 (TGF-β1), tumornecrosis factor (TNF), interferon gamma (IFN-γ) and B cell activatingfactor (BAFF). Exemplary nucleic acid biomarkers include, but are notlimited to, MHC class I chain-related protein A (MICA)-129 genotype andnegative regulator of T cell costimulation CTLA-4+49 A/G*GG genotype.

According to one embodiment, the circulating cells expressing the firstbiomarker are B lymphocytes with receptors that detect the firstbiomarker. According to another embodiment, the circulating cells arederived from the hematopoietic cell allograft. According to anotherembodiment, the receptors are antibodies.

According to one embodiment, the first biomarker is an antibodyexpressed by cells contained in the hematopoietic cell allograft.According to another embodiment, the cells expressing the firstbiomarker are B lymphocytes. According to another embodiment, thephenotype of the B lymphocytes is CD19⁺.

According to one embodiment, the antibody reacts with a second biomarkerexpressed by the patient's cells. According to another embodiment, thesecond biomarker is a Y-chromosome encoded H-Y antigen. According toanother embodiment, the H-Y antigen is DBY-2.

According to another embodiment, the recipient patient is male, therecipient's cells express the second biomarker, and the second biomarkeris the Y-chromosome encoded H-Y antigen, the donor is female, thedonor's cells express the first biomarker, and the first biomarker is anantibody, which binds to the second biomarker, which is the H-Y antigenexpressed by the patient's cells, wherein the recipient patient anddonor are genetically distinct. According to another embodiment, thedonor's cells that express the first biomarker are B lymphocytes.According to another embodiment, the phenotype of the B lymphocytes isCD19⁺.

According to one embodiment, the detecting of the first biomarkerexpressed by circulating cells of the patient precedes development ofcirculating antibodies to a donor cell antigen in the patient.

Detection of biomarkers may be accomplished by techniques known in theart, such as, without limitation, enzyme-linked immunosorbent assay(ELISA), Western blot, polymerase chain reaction (PCR), reversetranscription-polymerase chain reaction (RT-PCR), flow cytometry, andthe like.

According to one embodiment, the described invention provides the use offlow cytometry to analyze isolated PBMCs. Flow cytometry is a techniquefor counting and examining small particles such as cells by suspendingthem in a stream of fluid and passing them by an electronic detectionapparatus. Flow cytometry allows simultaneous multiparametric analysisof the physical and/or chemical characteristics of each individualparticle or cell. Measurable physical and/or chemical characteristicsinclude, but are not limited to, cell pigments (e.g., chlorophyll andphycoerythrin), total DNA content, total RNA content, DNA copy numbervariation, chromosome analysis and sorting, protein expression,localization and modification (e.g., phosphorylation), cell surfaceantigens (e.g., cluster of differentiation (CD) markers), intracellularantigens, nuclear antigens, enzymatic activity, apoptosis, cellviability, cell adherence (e.g., pathogen-host interaction) and thelike.

Briefly, a beam of light (e.g., laser light) of a single wavelength isdirected onto a hydrodynamically-focused stream of fluid. A number ofdetectors are aimed at the point where the stream passes through thelight beam; one detector in line with the light beam (i.e., forwardscatter), several detectors in perpendicular position (i.e., sidescatter) and at least one fluorescence detector. Each suspended cellpassing through the light beam scatters the light in some way, andfluorescent molecules (i.e., fluorophores) (e.g., naturally occurring orattached label or dye) may be excited into emitting light at a longerwavelength than the light source. The combination of scattered andfluorescent light is recorded by the detectors. The forward scattercorrelates with the cell volume, while the side scatter depends upon theinner complexity of the cell (e.g., shape of the nucleus).

One skilled in the art recognizes that a binding agent may be conjugatedto a compound that is useful, for example, in cell separation,therapeutic or diagnostic applications employing flow cytometry.Examples of binding agents include, but are not limited to, antibodies,avidin and streptavidin. By way of non-limiting example, a binding agentmay be conjugated to a label. The label may be any entity, the presenceof which can be readily detected. The label may include, but is notlimited to, a direct label, such as those described in detail in May etal., U.S. Pat. No. 5,656,503. Direct labels are entities which, in theirnatural state, are readily visible either to the naked eye, or with theaid of an optical filter and/or applied stimulation (e.g., laser light)to promote fluorescence. Non-limiting examples of direct labels includeradioactive, chemiluminescent, electroactive (e.g., redox labels) andfluorescent (i.e., fluorophore) compounds. Non-limiting examples offluorophores include Pacific Blue™, Alexa Fluor® 405, Pacific Orange™,Qdot® 525, Qdot® 565, Qdot® 605, Qdot® 655, Qdot® 705, Qdot® 800, AlexaFluor® 488, RPE (R-Phycoerythrin), RPE Texas Red®, RPE-Alexa Fluor® 610,TRI-COLOR®, RPE-Alexa Fluor® 700, RPE-Cy® 5.5, RPE-Cy® 7, Alexa Fluor®647, Alexa Fluor® 700, APC-Alexa Fluor® 750 and the like. A bindingagent may also be conjugated to, for example, a direct particulatelabel, such as a dye, metallic (e.g., gold) and colored latex particle.A binding agent may also be conjugated to, for example, a solid supportincluding, but not limited to, a magnetic bead.

Conjugation of a label to a binding agent may be accomplished bycovalent or non-covalent (including hydrophobic) bonding, or byadsorption. Techniques for conjugation are well-known in the art and maybe readily adapted for the particular reagents employed.

The data generated by flow cytometers may be plotted in a singledimension to produce a histogram or in two-dimensional orthree-dimensional plots. The regions on these plots may be sequentiallyseparated, for example, based on fluorescence intensity, by creating aseries of subset extractions termed “gates.” One skilled in the artrecognizes that specific gating protocols exist for diagnostic andclinical purposes, including, but not limited to, classification ofimmune system cells. By way of example, and without limitation, oneskilled in the art would recognize that it is possible to define a lightscattering gate to include only B lymphocytes by placing upper and lowerlimits on the forward and side scatter distributions.

Flow cytometers may use either light scattering in combination withfluorescence or light scattering only for analysis. Flow cytometers areavailable from a variety of commercial sources, including BD Biosciences(San Jose, Calif.), EMD Millipore (Billerica, Mass.), Life Technologies(Carlsbad, Calif.), Agilent (Santa Clara, Calif.), Miltenyi Biotec(Cambridge, Mass.) and the like.

It is understood that the described invention contemplates severalspecialized types of flow cytometry well-known in the art. Non-limitingexamples include fluorescence-activated cell sorting (FACS®),magnetic-activated cell sorting (MACS®) and high-dimensional flowcytometry.

FACS provides a method of sorting a heterogeneous mixture of cells intotwo or more containers, a single cell at a time, based upon the specificlight scattering and fluorescent characteristics of each cell. The useof multicolor, multiparameter FACS may employ primary conjugated bindingagents (e.g., antibodies) at defined fluorophore-to-protein ratios. Forexample, the following protocol may be used to perform FACS to detectantigen-specific B lymphocytes. PBMCs may be prepared in RPMI mediumcontaining 4% Fetal Calf Serum (FCS) (Gibco, Life Technologies,Carlsbad, Calif., Catalog No. 26010-074 or equivalent) and labeled for15-30 minutes at 4° C. with a combination of fluorophore-conjugatedmonoclonal antibodies (mAbs), such as APC-CD19 mAb (BD Biosciences, SanJose, Calif., Clone HIB19, No. 561742 or equivalent), Pacific Blue™-CD27mAb (BioLegend, San Diego, Calif., Clone 0323, No. 302821 orequivalent), PerCP Cy5.5-IgM mAb (BD Biosciences, San Jose, Calif.,Clone G20-127, No. 561285 or equivalent), FITC-Igλ mAb (BD Biosciences,San Jose, Calif., Clone JDC-12, No. 562053 or equivalent) and PE-Igκ mAb(BD Biosciences, San Jose, Calif., Clone G20-193, No. 562052 orequivalent). A 1:50 dilution for specific antibodies, and 1:200 dilutionfor IgM and IgG controls may be used. The samples may be analyzed by aFACSAria™ II (BD Biosciences, San Jose, Calif.).

MACS provides a cell separation technique in which cells that express aspecific surface antigen may be isolated from a heterogeneous mixture ofcells using magnetic particles coated with a binding agent (e.g.,antibody) that recognizes the specific surface antigen. For example, ina positive cell selection MACS technique, cells expressing the specificsurface antigen bind to the magnetic particles. After incubation withthe magnetic particles, the heterogeneous mixture of cells istransferred to a column placed in a magnetic field. The magnetic fieldcaptures the magnetic particles (including magnetic particles bound tocells expressing the specific surface antigen) while cells notexpressing the specific surface antigen (i.e., not bound to magneticparticles) may be eluted as flow through. For example, positiveselection involves isolation of cells (e.g., B lymphocytes) expressing aspecific surface antigen (e.g., CD19) from a heterogeneous mixture ofcells by binding the cells expressing the specific surface antigen tomagnetic particles coated with a binding agent (e.g., antibody) thatrecognizes the specific surface antigen.

It is understood by those in the art that MACS also provides negativeselection of cells. Negative selection, for example, involves theisolation and removal of undesired cells expressing a specific surfaceantigen from a heterogeneous mixture of cells by binding the cellsexpressing the specific surface antigen to magnetic particles coatedwith a binding agent (e.g., antibody) that recognizes the specificsurface antigen. A magnetic field captures the magnetic particles(including magnetic particles bound to undesired cells expressing thespecific surface antigen) while cells not expressing the specificsurface antigen (i.e., not bound to magnetic particles) may be elutedand collected.

One skilled in the art recognizes that various MACS products arecommercially available. These products include, but are not limited to,MACS microbeads (Miltenyi Biotec, Cambridge, Mass.), autoMACS® columns(Miltenyi Biotec, Cambridge, Mass.), autoMACS Pro Separator Instrument(Miltenyi Biotec, Cambridge, Mass.), and the like.

High-dimensional flow cytometry provides a method of sorting aheterogeneous mixture of cells into two or more containers, a singlecell at a time, using 6-12 fluorescent colors (i.e., fluorophores). Forexample, the following protocol may be used to perform FACS to detectantigen-specific B lymphocytes. Cryopreserved peripheral bloodmononuclear cell (PBMC) samples may be thawed and washed in deficientRPMI media supplemented with 4% FCS. Biotin-coupled antigen (DBY-2 orDBX-2) may be added to the cells and 20 minutes later, a “cocktail” offluorochrome conjugated monoclonal antibodies detecting CD19, CD21⁻,CD43, CD5, CD23, IgM and IgG, CD27 and dead cells may be added.Following 20 minute incubation, cells may be spun and washed andincubated for 20 min with fluorochrome-conjugated streptavidin. Data maybe collected for 1-5×10⁶ cells on a LSRII flow cytometer(BDBiosciences.com). The data may be analyzed using FlowJo(TreeStar.com) and further analyzed with Excel and Prism (GraphPadsoftware, Inc).

Most parameters measurable by flow cytometry can also be measured byother techniques well-known in the art. These techniques include, butare not limited to, analytical cytology (e.g., microfluorimetry),standard microscopic-based cytometric analysis, physical sorting (e.g.,panning), standard immunohistochemical techniques and the like.

The described invention provides the step of initiating immune therapyto mitigate symptoms or to treat recurrence of the cGvHD resulting fromthe transplant. Examples of immune therapy include, but are not limited,glucocorticoids, mycophenolate mofetil, sirolimus/rapamycin,2-deoxycoformycin, tacrolimus, rituximab, thalidomide,hydroxychloroquine, interleukin-2 (IL-2), extracorporeal photopheresis,imatinib, pentostatin, mesenchymal stem cells and the like. Exemplaryglucocorticoids include, but are not limited to, betamethasone,budesonide, cortisone, dexamethasone, hydrocortisone,methylprednisolone, prednisolone, prednisone, triamcinolone and thelike. Symptoms of cGvHD include, without limitation, dry eyes or visionchanges, dry mouth, white patches inside the mouth, and sensitivity tospicy foods, fatigue, muscle weakness and chronic pain, skin rash withraised, discolored areas, as well as skin tightening or thickening,shortness of breadth, vaginal dryness and weight loss.

According to one embodiment, patient samples are collected at least at90 days following HCT. According to another embodiment, patient samplesare collected at least at 95 days following HCT. According to anotherembodiment, patient samples are collected at least at 100 days followingHCT. According to another embodiment, patient samples are collected atleast at 100 days following HCT. According to another embodiment,patient samples are collected at least at 105 days following HCT.According to another embodiment, patient samples are collected at leastat 110 days following HCT. According to another embodiment, patientsamples are collected at least at 115 days following HCT. According toanother embodiment, patient samples are collected at least at 120 daysfollowing HCT. According to another embodiment, patient samples arecollected at least at 125 days following HCT. According to anotherembodiment, patient samples are collected at least at 130 days followingHCT. According to another embodiment, patient samples are collected atleast at 135 days following HCT. According to another embodiment,patient samples are collected at least at 140 days following HCT.According to another embodiment, patient samples are collected at leastat 145 days following HCT. According to another embodiment, patientsamples are collected at least at 150 days following HCT. According toanother embodiment, patient samples are collected at least at 155 daysfollowing HCT. According to another embodiment, patient samples arecollected at least at 160 days following HCT. According to anotherembodiment, patient samples are collected at least at 165 days followingHCT. According to another embodiment, patient samples are collected atleast at 170 days following HCT. According to another embodiment,patient samples are collected at least at 175 days following HCT.According to another embodiment, patient samples are collected at leastat 180 days following HCT. According to another embodiment, patientsamples are collected at least at 185 days following HCT. According toanother embodiment, patient samples are collected at least at 190 daysfollowing HCT. According to another embodiment, patient samples arecollected at least at 195 days following HCT. According to anotherembodiment, patient samples are collected at least at 200 days followingHCT. According to another embodiment, patient samples are collected atleast at 205 days following HCT. According to another embodiment,patient samples are collected at least at 210 days following HCT.According to another embodiment, patient samples are collected at leastat 215 days following HCT. According to another embodiment, patientsamples are collected at least at 220 days following HCT. According toanother embodiment, patient samples are collected at least at 225 daysfollowing HCT. According to another embodiment, patient samples arecollected at least at 230 days following HCT. According to anotherembodiment, patient samples are collected at least at 235 days followingHCT. According to another embodiment, patient samples are collected atleast at 240 days following HCT. According to another embodiment,patient samples are collected at least at 245 days following HCT.According to another embodiment, patient samples are collected at leastat 250 days following HCT. According to another embodiment, patientsamples are collected at least at 265 days following HCT. According toanother embodiment, patient samples are collected at least at 270 daysfollowing HCT. According to another embodiment, patient samples arecollected at least at 275 days following HCT. According to anotherembodiment, patient samples are collected at least at 280 days followingHCT. According to another embodiment, patient samples are collected atleast at 285 days following HCT. According to another embodiment,patient samples are collected at least at 290 days following HCT.According to another embodiment, patient samples are collected at leastat 295 days following HCT. According to another embodiment, patientsamples are collected at least at 300 days following HCT. According toanother embodiment, patient samples are collected at least at 305 daysfollowing HCT. According to another embodiment, patient samples arecollected at least at 310 days following HCT. According to anotherembodiment, patient samples are collected at least at 315 days followingHCT. According to another embodiment, patient samples are collected atleast at 320 days following HCT. According to another embodiment,patient samples are collected at least at 325 days following HCT.According to another embodiment, patient samples are collected at leastat 330 days following HCT. According to another embodiment, patientsamples are collected at least at 335 days following HCT. According toanother embodiment, patient samples are collected at least at 340 daysfollowing HCT. According to another embodiment, patient samples arecollected at least at 345 days following HCT. According to anotherembodiment, patient samples are collected at least at 350 days followingHCT. According to another embodiment, patient samples are collected atleast at 355 days following HCT. According to another embodiment,patient samples are collected at least at 360 days following HCT.According to another embodiment, patient samples are collected at leastat 365 days following HCT.

According to one embodiment, the time after therapy for detecting thefirst biomarker expressed by circulating cells of the patient is within1 year after transplantation. According to another embodiment, the timeafter therapy for detecting the first biomarker expressed by circulatingcells of the patient is within 180 days after transplantation. Accordingto another embodiment, the time after therapy for detecting the firstbiomarker expressed by circulating cells of the patient is within 155days after transplantation. According to another embodiment, the timeafter therapy for detecting the first biomarker expressed by circulatingcells of the patient is within 90 days after transplantation.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise, between the upper and lowerlimit of that range and any other stated or intervening value in thatstated range is encompassed within the invention. The upper and lowerlimits of these smaller ranges which may independently be included inthe smaller ranges is also encompassed within the invention, subject toany specifically excluded limit in the stated range. Where the statedrange includes one or both of the limits, ranges excluding either bothof those included limits are also included in the invention.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can also beused in the practice or testing of the present invention, the preferredmethods and materials are now described. All publications mentionedherein are incorporated herein by reference to disclose and describedthe methods and/or materials in connection with which the publicationsare cited.

It must be noted that as used herein and in the appended claims, thesingular forms “a”, “an”, and “the” include plural references unless thecontext clearly dictates otherwise. All technical and scientific termsused herein have the same meaning.

The publications discussed herein are provided solely for theirdisclosure prior to the filing date of the present application and eachis incorporated by reference in its entirety. Nothing herein is to beconstrued as an admission that the present invention is not entitled toantedate such publication by virtue of prior invention. Further, thedates of publication provided may be different from the actualpublication dates which may need to be independently confirmed.

EXAMPLES

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how tomake and use the present invention, and are not intended to limit thescope of what the inventors regard as their invention nor are theyintended to represent that the experiments below are all or the onlyexperiments performed. Efforts have been made to ensure accuracy withrespect to numbers used (e.g. amounts, temperature, etc.) but someexperimental errors and deviations should be accounted for. Unlessindicated otherwise, parts are parts by weight, molecular weight isweight average molecular weight, temperature is in degrees Centigrade,and pressure is at or near atmospheric.

Methods Human Subjects

Since Oct. 1, 2005, all allogeneic HCT patients were invited toparticipate in an ongoing IRB approved research protocol thatcryopreserves PBMC and plasma samples collected 3, 6, and 12 months(+/−15%) following F→M HCT in the BMT tissue bank at Stanford Stem CellTransplantation Laboratory. Because patients' clinic schedules vary, a15% leeway was allowed for each research sample collection time point.All samples were obtained from patients providing informed consent andthe research sample protocol was monitored by the Stanford UniversitySchool of Medicine Institutional Review Board. All patients suspected ofcGVHD development were evaluated in real-time by one of three dedicatedStanford cGVHD clinicians and further reviewed by cGVHD Scoringcommittee to uniformly apply NIH consensus cGVHD criteria (Filipovich AH, et al. (2005) National Institutes of Health consensus developmentproject on criteria for clinical trials in chronic graft-versus-hostdisease: I. Diagnosis and staging working group report. Biol BloodMarrow Transplant 11:945-956). For this retrospective study, weidentified a consecutive series of 28 male patients with female donorswho had enrolled on our research sample protocol with their transplantdates ranging Jan. 17, 2006-May 12, 2010, and who had survived at leastone year with research blood samples successfully collected 6 and 12months following HCT. All patients had undergone transplantation forlymphoid and blood malignancies and are described in Table 1.

Donor Chimerism Analysis

Donor chimerism analyses were performed on whole blood and PBMCsseparated into CD3, CD19, populations using Dynal-coated immunomagneticbeads. Donor engraftment used DNA genotyping of simple sequence-lengthpolymorphic markers that encode short tandem repeats, as describedpreviously (Millan M T, et al. (2002) Mixed chimerism andimmunosuppressive drug withdrawal after HLA-mismatched kidney andhematopoietic progenitor transplantation. Transplantation 73:1386-1391).

Detection of Serum Antibodies Reactive with DBY and DBY-2

The ELISA protocol that we use has been published (Miklos D B, et al.Antibody response to DBY minor histocompatibility antigen is inducedafter allogeneic stem cell transplantation and in healthy female donors.Blood 103:353-359; Miklos D B, et al. (2005) Antibody responses to H-Yminor histocompatibility antigens correlate with chronicgraft-versus-host disease and disease remission. Blood 105:2973-2978).Briefly, purified DBY, DBX, DBY-2 (KNDPERLDQQLANLDLNSEK) (SEQ ID NO: 1)and DBX-2 (ENALGLDQQFAGLDLNSSD) (SEQ ID NO: 2) (disparate amino acidsare bolded) and HIVp24 (negative control) proteins were coated onto96-well ELISA plates. The ELISA plates were blocked with 2% nonfat drymilk powder in tris buffered saline-tween 20 (TBST) for 2 hrs before thepatient plasma and controls were added. The plates were incubatedovernight at 4° C., washed and goat antihuman immunoglobulin G (IgG)conjugated to alkaline phosphatase was added to detect bound IgGantibodies. Finally, a chromogenic alkaline phosphatase substrate wasadded and the absorbance at 405 and 450 nm determined 30 min later. Datafor readings at 450 nm are reported to maintain continuity with previousassays. Values>3 s.d. above the mean for 32 healthy male donor sampleswere considered positive.

High-Dimensional Flow Cytometry Analysis

Cryopreserved peripheral blood mononuclear cell (PBMC) samples werethawed and washed in deficient RPMI media supplemented with 4% FCS.Greater than 90% viable PBMC were detected after thawing. Biotin-coupledantigen (DBY-2 or DBX-2) was added to the cells and 20 minutes later, a“cocktail” of fluorochrome conjugated monoclonal antibodies detectingCD19, CD21⁻, CD43, CD5, CD23, IgM and IgG, CD27 and dead cells wasadded. Following 20 minute incubation, cells were spun and washed andincubated for 20 min with fluorochrome-conjugated streptavidin. Data wascollected for 1-5×10⁶ cells on a LSRII flow cytometer(BDBiosciences.com). The data was analyzed using FlowJo (TreeStar.com)and further analyzed with Excel and Prism (GraphPad software, Inc).

Fluorescence Activated Cell Sorting (FACS-Sort)

PBMC were thawed and stained as described above. Antigen specific Bcells were sorted into FCS using a custom ARIAII (BDBioSciences.com)instrument. Approximately 70% of the sorted viable cells were recovered.

Culture Conditions

DBY-2 specific CD19+ B cells and CD3+ T cells were separately sortedwith FACS and cells were co-cultured (106/ml) in RPMI with 10% fetalcalf serum and DBY protein (0.05 μg/ml). IL-2 (50 IU/ml) and BAFF(RNDsystems.com) were tested at 10 ng/ml. Cultures were maintained at37° C. with 5% CO₂ in 5% O₂ incubators (Sahaf B, et al. (2008) Culturingof human peripheral blood cells reveals unsuspected lymphocyte responsesrelevant to HIV disease. Proc Natl Acad Sci USA 105:5111-5116).Harvested supernatant was stored at −80° C. before IgG ELISA assays.

Statistical Analyses

Non-parametric Kruskal-Wallis, Mann Whitney-U tests and Fisher Exacttest were used as indicated. The tests were performed in Prism (GraphPadSoftware, Inc).

Example 1 Retrospective Study Design

This study characterized a series of 28 consecutive female to malehematopoietic cell transplantation (F→M HCT) who consented to researchblood sample collection before transplant and had samples cryopreserved6 and 12 months after hematopoietic cell transplantation (HCT). Bloodresearch samples were tested without knowledge of patient diseasestatus, GVHD development or other clinical characteristics. Patientcharacteristics are described in Table 1.

Example 2 B Cells Circulating in F→M HCT Patients Express Immunoglobulin(Ig) Receptors Specific for DBY-2, an Immuno-Dominant Epitope in the DBYProtein

B cells circulating in F→M HCT patients express Ig receptors specificfor DBY-2, an immuno-dominant epitope in the DBY protein. The DBY-2peptide (KNDPERLDQQLANLDLNSEK) (SEQ ID NO: 1) contains the DBY-2 epitopefrequently recognized in allogeneic F→M antibody responses that occurfollowing HCT (Miklos D B, et al. Antibody response to DBY minorhistocompatibility antigen is induced after allogeneic stem celltransplantation and in healthy female donors. Blood 103:353-359; MiklosD B, et al. (2005) Antibody responses to H-Y minor histocompatibilityantigens correlate with chronic graft-versus-host disease and diseaseremission. Blood 105:2973-2978). Previous studies showed that 35% of F→Mpatients develop circulating IgG anti DBY-2 antibodies detectable byELISA six months to one year following HCT (Miklos D B, et al. Antibodyresponse to DBY minor histocompatibility antigen is induced afterallogeneic stem cell transplantation and in healthy female donors. Blood103:353-359). Extending this work, we used FACS analyses to revealcirculating live B cells expressing Ig receptors that specifically bindDBY-2, defined as those cells whose DBY-2 binding level is above athreshold defined by the Fluorescence Minus One (FMO) control. i.e., asample stained with all reagents except DBY-2 peptide (FIG. 1). Cellsexpressing either anti DBY-2 associated with Igκ or Igλ light chains bydefinition fall within this FMO gate. FIG. 1 shows the gating scheme anddata for a representative patient sample.

DBY-2 binding B cells (FIG. 1, lower left panel) were detected in 16 of28 (57%) PBMC samples collected 6 months following F→M HCT (FIG. 2). Asexpected, these DBY-2 B cells were not detected in PBMC from 15 healthymales where H-Y antigens are “self” antigens. DBY-2 B cells were notdetected in healthy female HCT donor PBMC samples (FIG. 3). Importantly,DBY-2 specific B cells were not detected following pre-incubation ofhigh-titer anti DBY-2 IgG with normal male donor PBMCs. We conclude theDBY-2 staining B cells observed after F→M HCT does not result fromindirect IgG binding but rather cell specific IgM expression. Cognizantthat immune reconstitution after myeloablative and nonmyeloablativeconditioning may differ, we included a similar number of 15myeloablative and 13 nonmyeloablative conditioned F→M patients, andtheir detection of DBY-2 specific B cells did not statistically differ(Table 2). As shown in FIG. 4A, the median absolute number of B cellsdetected 6 months following allo-HCT was 136/μl and ranged between 18and 400. The absolute number of CD19⁺ B cells did not statisticallydiffer in relation to conditioning intensity or donor relationship (datanot shown). The DBY-2 binding B cells collected from transplantpatients' blood are donor derived since both whole blood and CD19+ Bcells showed greater than 95% donor origin as measured by short tandemrepeat (STR) 3 months following transplantation.

TABLE 2 Univariable Analyses of DBY-2 B cells and DBY-2 IgG DevelopmentDBY-2 B cells aDBY-2 IgG+ within 1 y Day 180 post HCT 16/28 (57%) 14/28(50%) Conditioning Myeloablative 8/13 (62%) 6/13 (43%) Nonmyeloablative7/15 (47%) 9/15 (60%) ns‡ Donor Related 11/16 (67%) 9/16 (56%) Unrelated6/12 (42%) 5/12 (42%) ns‡ cGVHD None 1/8 (12.5%) 2/8 (25%) Mild 1/3(33%) 0/3 (0) Moderate 9/12 (75%) 8/12 (67%) Severe 5/5 (100%) p = 0.0044/5 (80%)* p = 0.01 *Comparing cGVHD (Severe, Moderate, Mild) againstnone ‡ns = not significant

The DBY-2 binding B cells in the transplant patients generally expressedboth Igκ and Igλ DBY-2 receptors. In the lower right panel in FIG. 1,the Igκ expressing anti DBY-2 cells are bounded by the square insert onthe left side of the figure and the Igλ expressing anti DBY-2 cells arebounded by the oval on the right. The amount of DBY-2 bound to cellswith Igλ-containing receptors tends to be proportional to the level ofreceptor expression on the cells, resulting in the “diagonal”distribution for DBY-2 binding cells that is visible when DBY2 bindingis plotted against Igλ expression (FIG. 1, lower right panel). The“tightness” of this diagonal suggests that the Igλ-containing receptorsfor DBY-2 are expressed at varied levels but that the binding avidity ofthe receptors is fairly similar. This diagonal pattern is expected formonoclonal antibodies or for a group of cells in which single or closelyrelated Ig sequences are responsible for the antigen binding. Diagonalpatterns were not observed with Igκ DBY-2 binding cells in any of thesubjects tested.

Example 3 Presence of B Cells with Receptors Specific for DBY-2 at Day180 Precedes Development of cGVHD in the Majority of F→M TransplantPatients

FIG. 2A schematically presents each patient's temporal development ofcGVHD in relation to their 6 and 12 month DBY-2 B cell measurements. Thedetection of DBY-2 B cells is highly associated with cGVHD (p=0.004;FIG. 2A). Considering the 16 patients in whom DBY-2 binding B cells weredetected 180 days following F→M HCT, 15 ultimately developed cGVHD. For6 patients, the “day 180” clinic visit was also their cGVHD diagnosisdate (ranging 155-182 days following HCT). The 9 others with DBY-2 Bcells detected were diagnosed with cGVHD at later clinic visits.Interestingly, the absolute and relative number of DBY-2 specific Bcells was significantly higher 6 months following HCT in patients whodeveloped moderate or severe cGVHD compared to those with mild cGVHD ornone (p=0.02; FIG. 4B). In these 28 F→M HCT, none had cGVHD diagnosedbefore their 6 months sample collection. It may be important that ourearliest diagnosis of cGVHD was 155 days after HCT, since cGVHD cansometimes develop as early as 90 days following HCT, but our limitedpatients sample did not happen to include such early cGVHD. Whilesamples collected at 90 days following HCT were available for only 8patients, we have included this limited day 90 data in FIG. 2A because3/9 had detectable DBY-2 B cells and suggests that follow-up studiesshould include samples collected as early as 90 days following HCT.

Example 4 The Detection of DBY-2 Specific B Cells Precedes theDevelopment of Circulating Anti-DBY Antibodies

As expected, the majority (11 of 14) of the F→M transplant patients whohad anti DBY-2 IgG develop within 1 year post HCT also had DBY-2specific B cells detected 180 days following HCT (FIG. 2B).Interestingly, the number of patients who had anti DBY-2 B cellsdetected from PBMC collected one year post transplant was than lowerthan the day 180 frequency (FIG. 2B). This may be due to the migrationof cells from blood into lymphoid organs. Additionally, the cells mayhave been eliminated by treatment for cGVHD.

Example 5 The Detection of Anti-DBY-2 IgG within One Year Post F→M HCTAssociates with cGVHD Development

Circulating anti DBY-2 IgG was detected in plasma collected from 14 of28 (50%) patients within one year of transplant. As we previouslyreported for allogeneic IgG developing against any of five full-lengthH-Y antigens(20) the detection of anti DBY-2 IgG associated with thedevelopment of cGVHD (p=0.002) and did not associate with patient'sprimary disease, conditioning regimen, or donor relationship (Table 2).None of these 28 F→M HCT patients had DBY-2 IgG detected in their 6month samples when already 16 of 28 (57%) had detectable DBY-2 B cells.Our demonstration that these DBY-2 specific B cells appear prior todevelopment of both their corresponding IgG and cGVHD suggests thatdetection of anti DBY-2 B cells may predict cGVHD with clinical utility.

Example 6 IgG that Binds DBY Protein and DBY-2 Peptide is SecretedFollowing Ex Vivo Stimulation of FACS-Sorted Anti-DBY-2 Specific B Cells

FACS sorted DBY-2 binding B cells cultured with DBY protein plus IL-2, Bcell activating factor (BAFF) and autologous T cells for seven dayssecreted ELISA-detectable IgG that specifically detected DBY-2 and thefull-length DBY protein (FIG. 5, upper panel). Both the intact DBYprotein and autologous T cells were required for this stimulation sincevirtually no detectable antibody was produced if either was omitted fromthe culture. In contrast, BAFF was helpful but not necessary forantibody production (FIG. 5, lower panel). The requirement for T cellsand the full-length protein antigen suggests that this anti DBY-2response is T-dependent.

Example 7 FACS Phenotype of the DBY-2 Binding B Cells in F→M Patients

The median frequency of DBY-2 binding B cells in the F→M patients is0.7% (0.3-1.0%) of CD-19 B cells (FIG. 4A). This relatively highfrequency is in the range (>0.1%) frequently observed for antigenreactive cells in immunized hosts. Nevertheless, the phenotype of thesecells corresponds to the commonly accepted phenotype for naïve B cellsin man, i.e., CD19⁺IgM⁺IgD⁺CD27⁻CD38⁺CD5⁻ (FIG. 6). None of the DBY-2binding B cells in the F→M HCT patients express CD27, which is typicallyexpressed on memory B cells. However, occasional blood samples drawnwhen GVHD is present contained cells expressing the typical phenotypefor isotype-switched plasmablasts (CD19⁺IgM⁺IgD⁺Igλ⁺CD27⁺CD38⁺CD5⁻).

TABLE 3 Antibody Characteristics for the Marker Combinations in Hi-DFACS Antigen Fluorochrome Source CD19 APC BD Biosciences CD56 Cy5PEBioLegend CD14 Cy5PE BioLegend CD3 Cy5PE BioLegend IgD Alexa 700BioLegend, as purified anitbody IgM PecP CY5.5 BD Biosciences CD38Cy7PE/or Qdot655 BD Biosciences CD27 Pacific-Blue BioLegend Ig LambdaFITC BD Biosciences Ig Kappa PE BD Biosciences

DISCUSSION

This study reports a FACS method pairing antigen specific staining withpaired B cell receptor detection using lambda/kappa light chaindetection to identify a high frequency alloreactive donor B cell bindingDBY-2 that develops following allogeneic F→M HCT and is not detected innormal male or female donors. These cells were detected in fifteen ofsixteen F→M HCT recipients who developed chronic graft versus hostdisease (cGVHD). In contrast, they were only detected in one of eightpatients who did not develop cGVHD. Thus we conclude that the presenceof B cells with receptors that recognize the DBY-2 is positivelyassociated with development of cGVHD (p<0.004, Fisher Exact Test).

Previous studies have shown that H-Y antibody develop following F→M HCTin association with cGVHD (Miklos D B, et al. (2005) Antibody responsesto H-Y minor histocompatibility antigens correlate with chronicgraft-versus-host disease and disease remission. Blood 105:2973-2978),and here we show immune dominant peptide epitope DBY-2 was similarlyrecognized by IgG in 50% of these 28 F→M HCT patients and associatedwith cGVHD (p=0.002). However, these H-Y IgG antibodies are rarelydetected prior to the onset of GVHD and thus are unlikely to have cGVHDpredictive value. In contrast, this study identifies B cells thatexpress IgM and IgG receptors specific for DBY-2 and show that thesealloantigen binding B cells often precede the onset of cGVHD. Thus,their presence in a patient may warrant pre-emptive cGVHD therapy.

The role that DBY-2 binding B cells play in the cGVHD disease process isunclear. They may simply be bystanders that are induced by mechanismsthat activate T cells that may actually mediate cGVHD. However, ourobservation that they commonly preceded cGVHD developments suggests thatthey may play an early pathogenic role. In fact, as recent findings withmouse GVHD models suggest, they may play a role in antigenpresentation(23) necessary for stimulation of pathogenic T cell clonalexpansion and/or induction of inflammatory cytokine production andalloreactive antibody production (Young J S, et al (2012) Donor B cellsin transplants augment clonal expansion and survival of pathogenic CD4+T cells that mediate autoimmune-like chronic graft-versus-host disease.J Immunol 189:222-233; Srinivasan M, et al. (2011) Donor B-cellalloantibody deposition and germinal center formation are required forthe development of murine chronic GVHD and bronchiolitis obliterans.Blood 119:1570-1580).

The DBY-specific B cells are found in F→M transplant patients where, byvirtue of the sex mismatch between donor and host, the donor B cells areextensively exposed to the host DBY protein and its component DBY-2peptide. Consistent with this argument, the DBY-2 binding B cells in theF→M patients are present at the relatively high frequencies common forantigen reactive cells generated in response to an antigenic stimulus.

Basically, the presence of DBY-2 binding B cells in F→M patients wouldlead us to believe that they are memory B cells that developed fromnaïve female donor B cells when they encountered the host DBY-2 antigen.However, the phenotype of these anti DBY-2 B cells corresponds to thecommonly accepted phenotype for human naïve or transitional B cells(CD19⁺IgD⁺IgM⁺CD27⁻CD38⁺CD5⁻) (Kuzmina Z, et al. (2011) Significantdifferences in B-cell subpopulations characterize patients with chronicgraft-versus-host disease-associated dysgammaglobulinemia. Blood117:2265-2274; Sarantopoulos S, et al. (2007) High levels of B-cellactivating factor in patients with active chronic graftversus-hostdisease. Clin Cancer Res 13:6107-6114; Sarantopoulos S, et al. (2011)Recovery of B-cell homeostasis after rituximab in chronicgraft-versus-host disease. Blood 117:2275-2283; Sarantopoulos S, et al.(2009) Altered B-cell homeostasis and excess BAFF in human chronicgraft-versushost disease. Blood 113:3865-74; Young J S, et al (2012)Donor B cells in transplants augment clonal expansion and survival ofpathogenic CD4+ T cells that mediate autoimmune-like chronicgraft-versus-host disease. J Immunol 189:222-233) that have recentlyemerged from bone marrow and are on their way to lymphoid organs.Although these B cells may ultimately give rise to the plasma cells thatproduce the IgG anti DBY-2 found in circulation later in the disease,their current phenotype belies this fate. Future studies may help toresolve this paradox.

In summary, we show here for the first time that F→M HCT patientscommonly develop donor B cells with Ig receptors that recognize hostmale antigens. These B cells, which develop prior to, or concurrent withthe onset of cGVHD, precede the onset of antibodies production to maleH-Y antigens. These findings may provide a mechanistic explanation forthe moderate efficacy of in vivo B cell depletion in treating cGVHD, andfurther suggests that more focused B cell targeting, e.g., with DBY-2 inF→M HCT, might be more effective cGVHD therapy. In addition, theprospective monitoring of anti DBY-2 B cells may direct a more effectiveschedule for alloreactive B cell depletion therapy towards a goal ofcGVHD prevention. Finally, DBY-2 B cell monitoring will help elucidatewhether current in vivo B cell depletion therapy for cGVHD effectivelydepletes these alloreactive B cells or if they persist and proliferatewhen cGVHD recurs.

What is claimed is:
 1. A method for warning of onset of chronic graftversus host disease (cGvHD) prior to appearance of symptoms of cGvHD ina patient following a hematopoietic cell transplantation therapy with ahematopoietic cell allograft, comprising: (a) isolating peripheral bloodmononuclear cells (PBMCs) from the patient at a time after the therapy;(b) analyzing the isolated PBMCs, and specifically detecting a firstbiomarker expressed by circulating cells of the patient that reacts witha second biomarker expressed by genetically distinct cells, wherein thedetecting of the cells that express the first biomarker indicates likelyimminent onset of cGVHD in the patient; and (c) initiating immunetherapy to mitigate symptoms of cGvHD resulting from the transplant. 2.The method according to claim 1, wherein the circulating cellsexpressing the first biomarker are B lymphocytes with receptors thatdetect the first biomarker.
 3. The method according to claim 1, whereinthe circulating cells are derived from the hematopoietic cell allograft.4. The method according to claim 2, wherein the first biomarker is anantibody, the hematopoietic cell allograft contains cells that expressthe antibody, and the antibody reacts with the second biomarkerexpressed by the patient's cells.
 5. The method according to claim 4,wherein the second biomarker is a Y-chromosome encoded H-Y antigen. 6.The method according to claim 5, wherein the H-Y antigen is DBY-2. 7.The method according to claim 5, wherein the recipient patient is male,the recipient's cells express the second biomarker, and the secondbiomarker is the Y-chromosome encoded H-Y antigen, the donor is female,the donor's cells express the first biomarker, and the first biomarkeris an antibody, which binds to the second biomarker, which is the H-Yantigen expressed by the patient's cells. wherein the recipient patientand donor are genetically distinct.
 8. The method according to claim 7,wherein the donor's cells that express the first biomarker are Blymphocytes.
 9. The method according to claim 8, wherein phenotype ofthe B lymphocytes is CD19⁺.
 10. The method according to claim 1, whereinthe time after therapy for detecting the first biomarker expressed bycirculating cells of the patient is within 1 year after transplantation.11. The method according to claim 1, wherein the time after therapy fordetecting the first biomarker expressed by circulating cells of thepatient is within 180 days after transplantation.
 12. The methodaccording to claim 1, wherein the time after therapy for detecting thefirst biomarker expressed by circulating cells of the patient is within155 days after transplantation.
 13. The method according to claim 1,wherein time after therapy for detecting of the first biomarkerexpressed by circulating cells of the patient is within 90 days aftertransplantation.
 14. The method according to claim 1, wherein detectingof the first biomarker expressed by circulating cells of the patientprecedes development of circulating antibodies to a donor cell antigenin the patient.
 15. The method according to claim 1, wherein analyzingstep (b) is performed using flow cytometry.
 16. A method for warning ofrecurrence of chronic graft versus host disease (cGvHD) prior toappearance of symptoms of cGvHD in a patient who, followinghematopoietic cell transplantation therapy with a hematopoietic cellallograft, developed and was treated for cGvHD, which is in remission,comprising: (a) isolating peripheral blood mononuclear cells (PBMCs)from the patient at a time after the therapy; (b) analyzing the isolatedPBMCs, and specifically detecting a first biomarker expressed bycirculating cells of the patient that reacts with a second biomarkerexpressed by genetically distinct cells, wherein the detecting of thecells that express the first biomarker indicates likely imminent onsetof cGvHD in the patient; and (c) initiating immune therapy to treat therecurrence of the cGvHD resulting from the transplant.
 17. The methodaccording to claim 16, wherein the circulating cells expressing thefirst biomarker are B lymphocytes with receptors that detect the firstbiomarker.
 18. The method according to claim 16, wherein the circulatingcells are derived from the hematopoietic cell allograft.
 19. The methodaccording to claim 17, wherein the first biomarker is an antibody, thehematopoietic cell allograft contains cells that express the antibody,and the antibody reacts with the second biomarker expressed by thepatient's cells.
 20. The method according to claim 19, wherein thesecond biomarker is a Y-chromosome encoded H-Y antigen.
 21. The methodaccording to claim 20, wherein the H-Y antigen is DBY-2.
 22. The methodaccording to claim 20, wherein the recipient patient is male, therecipient's cells express the second biomarker, and the second biomarkeris the Y-chromosome encoded H-Y antigen, the donor is female, thedonor's cells express the first biomarker, and the first biomarker is anantibody, which binds to the second biomarker, which is the H-Y antigenexpressed by the patient's cells. wherein the recipient patient anddonor are genetically distinct.
 23. The method according to claim 22,wherein the donor's cells that express the first biomarker are Blymphocytes.
 24. The method according to claim 23, wherein phenotype ofthe B lymphocytes is CD19⁺.
 25. The method according to claim 16,wherein the time after therapy for detecting the first biomarkerexpressed by circulating cells of the patient is within 1 year aftertransplantation.
 26. The method according to claim 16, wherein the timeafter therapy for detecting the first biomarker expressed by circulatingcells of the patient is within 180 days after transplantation.
 27. Themethod according to claim 16, wherein the time after therapy fordetecting the first biomarker expressed by circulating cells of thepatient is within 155 days after transplantation.
 28. The methodaccording to claim 16, wherein time after therapy for detecting of thefirst biomarker expressed by circulating cells of the patient is within90 days after transplantation.
 29. The method according to claim 16,wherein detecting of the first biomarker expressed by circulating cellsof the patient precedes development of circulating antibodies to a donorcell antigen in the patient.
 30. The method according to claim 16,wherein analyzing step (b) is performed using flow cytometry.